Amunix Pharmaceuticals raises $117 million to pivot to cancer drugs - San Francisco Business Times bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Ruddock had been promoted to head of consultant relations for Australia.
He had been playing an increased role in broadening the relationships with institutional asset consultants in addition to his role of managing retail research.
In his new role, Ruddock would continue to work to deepen relationships with both local and global consultants and connect them with the company’s investment teams.
Ahmed had been promoted to senior client account manager and was a part of the client account management team led by Harry Wall.
Matt Gaden, Janus Henderson head of Australia, said with the ongoing consolidation in the market leading to fewer but larger funds, it had become increasingly important the firm were able to connect with the market and clients to solve problems or challenges, as opposed to simply pushing a product.
Print
DTx Pharma, a 15-employee San Diego biotechnology company pursuing a platform for creating RNA-based therapies to treat genetic drivers of rare diseases, said Monday that it has raised $100 million in Series B round of financing.
The early stage company, which previously raised $10.6 million in a Series A round in January 2020, is pursuing potential treatments in ophthalmology and for neuromuscular diseases initially.
According to DTx Pharma’s website, its most advanced program in the eye arena targets a disease called retinitis pigmentosa, which is often inherited. It anticipates initiating clinical work on this treatment in 2022.
In the neuromuscular area, the company is looking into multiple diseases driven by genetic defects in skeletal muscle, cardiac muscle and the peripheral nervous system. It expects to move its first neuromuscular disease candidates into clinical development in 2023.
Artiva Biotherapeutics Finds $120M In Series B socaltech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from socaltech.com Daily Mail and Mail on Sunday newspapers.
Posted on 199
During the worst crisis since World War II, US dividends proved resilient, increasing 2.6% year-over-year to a record high of $503.1 billion in 2020, as just one in fourteen US companies cancelled its dividend between April and December according to the latest edition of the Janus Henderson Global Dividend Index.
(Graphic: Business Wire)
Globally, dividends fell to $1.26 trillion during the year, down 12.2% on a headline basis. This was better than Janus Henderson’s best-case forecast of $1.21 trillion thanks to a less severe fall in Q4 payouts than anticipated. Janus Henderson’s index of global dividends fell to 172.4, a level last seen in 2017.